Léčba maligního mezoteliomu pleury v České republice

KOLEK, Vítězslav, Oldřich FISCHER, Ivona GRYGÁRKOVÁ, M. BAŘINOVÁ, Renata CHLOUPKOVÁ, J. KREJČÍ, Michal HRNČIARIK, Miloš PEŠEK, Jaromír ROUBEC, I. JANÍČKOVÁ, Jana SKŘIČKOVÁ, Marcela TOMÍŠKOVÁ, Leona KOUBKOVÁ, Dimka SIXTOVÁ, M. ČERNOVSKÁ, L. HAVEL, M. ZEMANOVÁ, Helena ČOUPKOVÁ, D. DOLEŽAL a T. TŮZOVÁ. Léčba maligního mezoteliomu pleury v České republice. Studia pneumologica et phthiseologica. Praha: Trios s.r.o., 2019, roč. 79, č. 3, s. 82-87. ISSN 1213-810X.

Základní údaje

Originální název

Léčba maligního mezoteliomu pleury v České republice

Název anglicky

Treatment of malignant pleural mesothelioma in the Czech Republic

Autoři

KOLEK, Vítězslav (203 Česká republika, garant), Oldřich FISCHER (203 Česká republika), Ivona GRYGÁRKOVÁ (203 Česká republika, domácí), M. BAŘINOVÁ (203 Česká republika), Renata CHLOUPKOVÁ (203 Česká republika, domácí), J. KREJČÍ (203 Česká republika), Michal HRNČIARIK (203 Česká republika), Miloš PEŠEK (203 Česká republika), Jaromír ROUBEC (203 Česká republika), I. JANÍČKOVÁ (203 Česká republika), Jana SKŘIČKOVÁ (203 Česká republika, domácí), Marcela TOMÍŠKOVÁ (203 Česká republika), Leona KOUBKOVÁ (203 Česká republika), Dimka SIXTOVÁ (203 Česká republika), M. ČERNOVSKÁ (203 Česká republika), L. HAVEL (203 Česká republika), M. ZEMANOVÁ (203 Česká republika), Helena ČOUPKOVÁ (203 Česká republika), D. DOLEŽAL (203 Česká republika) a T. TŮZOVÁ (203 Česká republika)

Vydání

Studia pneumologica et phthiseologica, Praha, Trios s.r.o. 2019, 1213-810X

---

Další údaje

Jazyk

čeština

Typ výsledku

Článek v odborném periodiku

Obor

30203 Respiratory systems

Stát vydavatele

Česká republika

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Kód RIV

RIV/00216224:14110/19:00110659

Organizační jednotka

Lékařská fakulta

Klíčová slova česky

maligní mezotemiom pleury; chemoterapie; přežití; prognostické faktory

Klíčová slova anglicky

Chemotherapy; Malignant pleural mesothelioma; Survival prognostic factors

Štítky

rivok

Příznaky

Mezinárodní význam, Recenzováno

---

Anotace

V originále

Malignant pleural mesothelioma (MPM) is the most frequent primary tumor of this anatomical structure. It is usually caused by exposure to asbestos and the incidence continues to rise despite the fact that work with asbestos is banned in European countries. Presented is a set of data on consecutive patients treated with standard first-line cisplatin/pemetrexed chemotherapy in Czech centers. Another sample comprised patients receiving second-line pemetrexed therapy. Data from 2008-2018 were analyzed at the Institute of Biostatistics and Analyses in Brno. The study included 249 and 35 patients receiving first- A nd second-line therapy, respectively. There were 66 females and 183 males with a mean age of 64 years. Occupational and non-occupational exposure to asbestos was confirmed in 58 and 23 cases, respectively; no exposure was found in 168 patients. The most common histological types were epithelioid MPM in 167 patients, mixed in 26 and sarcomatoid in 16 patients; no histological type was determined in 40 subjects. There were 23 patients with TNM stage I, 41 with stage II, 64 with stage III and 115 with stage IV. For the entire sample, the median progression-free survival was 9.6 months and median overall survival (OS) was 20.1 months. Patient survival was affected by the TNM stage and histological type of the tumor. For the second-line therapy, the median OS was 9.9 months. It may be concluded that the prognosis of patients with malignant mesothelioma is still not satisfactory and new treatment options need to be sought. Comments on outcomes of some recent studies are added. © 2019 Trios spol. s.r.o.. All rights reserved.

Anglicky

Malignant pleural mesothelioma (MPM) is the most frequent primary tumor of this anatomical structure. It is usually caused by exposure to asbestos and the incidence continues to rise despite the fact that work with asbestos is banned in European countries. Presented is a set of data on consecutive patients treated with standard first-line cisplatin/pemetrexed chemotherapy in Czech centers. Another sample comprised patients receiving second-line pemetrexed therapy. Data from 2008-2018 were analyzed at the Institute of Biostatistics and Analyses in Brno. The study included 249 and 35 patients receiving first- A nd second-line therapy, respectively. There were 66 females and 183 males with a mean age of 64 years. Occupational and non-occupational exposure to asbestos was confirmed in 58 and 23 cases, respectively; no exposure was found in 168 patients. The most common histological types were epithelioid MPM in 167 patients, mixed in 26 and sarcomatoid in 16 patients; no histological type was determined in 40 subjects. There were 23 patients with TNM stage I, 41 with stage II, 64 with stage III and 115 with stage IV. For the entire sample, the median progression-free survival was 9.6 months and median overall survival (OS) was 20.1 months. Patient survival was affected by the TNM stage and histological type of the tumor. For the second-line therapy, the median OS was 9.9 months. It may be concluded that the prognosis of patients with malignant mesothelioma is still not satisfactory and new treatment options need to be sought. Comments on outcomes of some recent studies are added. © 2019 Trios spol. s.r.o.. All rights reserved.